Search research articles
Contact Us
Filters
Showing results (351-360 of 391) with videos related to
Page
of 40
Sort By:
Leukemia
|
October 3, 2009
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R Fonseca, P L Bergsagel, J Drach, et al.
Leukemia Research
|
August 23, 2005
Ploidy status rarely changes in myeloma patients at disease progression
W J Chng, J M Winkler, P R Greipp, et al.
Blood Cancer Journal
|
August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
S K Kumar, B LaPlant, V Roy, et al.
Leukemia
|
September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M Q Lacy, S R Hayman, M A Gertz, et al.
British Journal of Haematology
|
January 16, 2007
6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis
E M Ocio, R F J Schop, B Gonzalez, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
June 9, 2016
Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study
A Sepriano, S Ramiro, D van der Heijde, et al.
Leukemia
|
November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
A Dispenzieri, G A Wiseman, M Q Lacy, et al.
Journal of Medicinal Chemistry
|
June 10, 2011
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia
Christopher J Helal, Zhijun Kang, Xinjun Hou, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions
Jamison B Tuttle, Marie Anderson, Bruce M Bechle, et al.
Journal of Medicinal Chemistry
|
October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors
Michelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.
Page
of 40
Search research articles
Search
Showing results (351-360 of 391) with videos related to
Sort By:
Page
of 40
Leukemia
|
October 3, 2009
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R Fonseca, P L Bergsagel, J Drach, et al.
Leukemia Research
|
August 23, 2005
Ploidy status rarely changes in myeloma patients at disease progression
W J Chng, J M Winkler, P R Greipp, et al.
Blood Cancer Journal
|
August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
S K Kumar, B LaPlant, V Roy, et al.
Leukemia
|
September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M Q Lacy, S R Hayman, M A Gertz, et al.
British Journal of Haematology
|
January 16, 2007
6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis
E M Ocio, R F J Schop, B Gonzalez, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
June 9, 2016
Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study
A Sepriano, S Ramiro, D van der Heijde, et al.
Leukemia
|
November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
A Dispenzieri, G A Wiseman, M Q Lacy, et al.
Journal of Medicinal Chemistry
|
June 10, 2011
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia
Christopher J Helal, Zhijun Kang, Xinjun Hou, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions
Jamison B Tuttle, Marie Anderson, Bruce M Bechle, et al.
Journal of Medicinal Chemistry
|
October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors
Michelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.
Page
of 40